Presenting Companies
Filip Peters
CEO
Acorai Heart Monitor (Helsingborg, Skane Lan, Sweden) is the first handheld, scalable and non-invasive intracardiac pressure monitor, enabling improved health equity and patient outcomes. Acorai Heart Monitor is accompanied by the SAVE Sensor System, which is the hardware multi-sensor system in the device. Data is collected from Seismic, Acoustic, Visual and Electric sensors, which together with the proprietary machine learning architecture, can demonstrate the direct estimates of the intracardiac pressures; the most accepted way of managing heart failure patients.
Therapeutic: Cardiovascular
Yvonne Bokelman
CEO
Alyve Medical (Denver, CO USA) is at the forefront of transforming musculoskeletal rehabilitation and motion assessment with cutting-edge technologies. Alyve revolutionizes musculoskeletal rehab with Neuralign S™, a groundbreaking therapeutic wearable. It's the next generation of neuromuscular electrical stimulation (NMES), powered by their patented Motion Activated Stimulation™ for superior, sustained results. Targeting shoulder pain, a top musculoskeletal concern, Alyve taps into a $10B global market. With a strong and experienced executive leadership team, Alyve, while early stage, already boasts global traction, regulatory clearances, revenues, and independent supporting clinical data.
Therapeutic: Orthopedics-Spine; Orthopedic Rehabilitation
Anu Parvatiyar
Cofounder & CEO
Ananya Health (San Francisco, CA) is building a self-contained cryoablation device to freeze abnormal cells in the cervix and prevent them from becoming cervical cancer, without any consumable cryogen. Our proprietary platform enables nurses and PAs to achieve standard of care outcomes 10x cheaper than traditional cryo, bringing access to cancer prevention to more women in more places.
Therapeutic: Women’s Health
Upma Sharma
President & CEO
Arsenal Medical (Waltham, MA) is a clinical-stage platform company that develops biomaterials for underserved clinical needs. Founded by luminaries Robert Langer, George Whitesides, and Carmichael Roberts, Arsenal’s vision is to transform medical devices using materials innovation. Our lead products are in the multi-billion dollar neurovascular and trauma markets, and their scientific foundation has been validated by substantial non-dilutive support from partners like DARPA and NIH.
Therapeutic: Biomaterials, Neurovascular
Moses Cesario
CEO
Butterfly.bio (Marina Del Rey, California, USA) was founded to modernize techniques and procedures associated with women’s reproductive healthcare. Today, the standard of care for general gynecologic procedures and fertility treatments are surgical. Butterfly has developed a hysteroscopy-based approach that removes the need for surgery. Our mission is to bring not one but a host of updated products & technologies to women’s reproductive health that embrace the state of the art in medical device, diagnostics and artificial intelligence. Through our products physicians will deliver an increased quality of care, lower costs and move treatments towards prevention and away from treatment of an advanced disease state. It is time to bring women’s health into the 21st century.
Therapeutic: Women’s Health; Fertility
Jon Greenwald
CEO
Caira® Surgical is pioneering the development of novel Radar Surgical Tracking and fast anatomic landmark registration to improve precision and accuracy in orthopedic surgery and revolutionize the usability, economics, and access to advanced surgical navigation and robotics. The company's first product, Radar Surgical Navigation™ for Total Knee Replacement, employs Caira's proprietary sub-millimeter-accurate Radar Surgical Tracking featuring our Radar Beacons™ that fit within the primary incision, eliminating invasive bone pins and additional incisions inherent to incumbent systems. Caira's proprietary technology eliminates line-of-sight interference and enables a simple workflow that significantly reduces operative time and decreases capital equipment and disposable costs by up to 10x compared to incumbent systems.
Therapeutic: Orthopedics-Spine
Evan Luxon
CEO
Centese (Omaha, NE, USA) has developed Thoraguard, a digital medical device that transforms the recovery process for patients undergoing cardiothoracic surgery. The device is 510(k) cleared, has been used in over 5,000 patients, and has strong clinical evidence demonstrating a 1-day reduction in length of stay in thoracic surgery and 30% reduction in the rate of post-op AFib in cardiac surgery. Thoraguard’s initial users include some of the top cardiothoracic surgeons in the world, who have enthusiastically endorsed the system.
Therapeutic: Thoracic Surgery, Cardiac Surgery
Howard Carolan
Co-founder & CEO
CoapTech (Baltimore, MD, USA) has commercialized a high-margin (85%+ GM), high-growth medical device called the PUMA System. The FDA-cleared PUMA-G device has been demonstrated in peer-reviewed studies to save hospitals ~$25,000 per patient. This disposable device enables bedside physicians using ultrasound (instead of specialists/surgeons in specialty suites) to place percutaneous feeding tubes. CoapTech has seen steady growth in product sales and is raising capital to expand its sales team and to develop other devices and procedures building on the PUMA minimally-invasive surgery platform.
Therapeutic: Minimally Invasive Surgery, Critical Care / Ultrasound
Bill Perry
CEO
Deep Blue (Durham, NC / San Francisco, CA, USA) is transforming soft tissue surgery by launching next generation surgical devices for optimal tissue tension, reinforcement, and defect closure. Our platform has three pillars: the T-Line® Hernia Mesh portfolio, the T-Line® TCS (Tissue Control Suture) portfolio and the T-Line® Breast Scaffold. Failure in soft tissue surgery due to suture pull-through is common, is painful for the patient, and is often related to a lack of fast, reliable reinforcement that reduces tissue stress at the surgical site.
Therapeutic: Surgery, Plastic Surgery/Aesthetic
Niraj Varma
COO
Cardiac resynchronisation therapy (CRT) is an existing device-based therapy for heart failure patient with ventricular dyssynchrony. CRT suffers from a failure rate of 30% and more. This is the issue we at EP Solutions (Yverdon-les-Bains, VD, Switzerland) are addressing: We are developing a noninvasive planning tool that boosts the success rate of CRT. The implantation plan tells the implanting physician ahead of time where to implant the CRT electrode for the therapy to be successful, and how to access that location.
Therapeutic: Cardiovascular
Sergey Kanareykin
Director, Business and Finance
Euclid Beamlabs (Bolingbrook, IL) develops next-generation medical, electron microscopy, and high-energy devices that obtain the highest performance from the smallest packages. Our newly developed electronic brachytherapy (EB) device replaces typical LDR designs with an ultra-lightweight 1 MeV linac design capable of HDR EB from X-ray radiation with mean energy of 300 to 400 KeV. Euclid’s technology can immediately retrofit LDR EB equipment (accelerator upgrade) or be developed to a full HDR EB or IORT (intraoperative radiation therapy) system for healthcare professionals.
Therapeutic: Oncology, Surgical Oncology, Robotics
Max Ostermeier
CEO & Founder
Implandata Ophthalmic Products GmbH (San Diego, California, USA) is transforming the care of glaucoma patients by introducing remote disease monitoring and management with their game-changing EYEMATE system. Eye doctors are enabled to remotely manage their patients and to personalize therapy. Patients are empowered via self-monitoring, resulting in improved therapy adherence. The product is CE marked and currently launched in Europe. It has obtained FDA Breakthrough Device Designation and existing CPT codes for remote patient monitoring are applicable.
Therapeutic: Glaucoma, Remote Patient Monitoring, Ophthalmology
Samantha Scott
Founder & CEO
JuneBrain Inc. (Baltimore, MD, USA) provides accessible monitoring for eye care and neurology. We have created the Neuro-i: an AI-driven, wearable eye-scanning device and SaaS platform to detect new disease activity and enable clinicians to track disease progression and patient responses to treatment between clinical visits. The Neuro-i is patented and currently undergoing clinical testing for 510(k) clearance by the FDA. Our company has $300k+ in sales backlog and we have secured $2.9M in funding, including $1.7M in NSF SBIR awards.
Therapeutic: Imaging; Neurology, Ophthalmology, Remote Patient Monitoring, Artificial Intelligence, Digital Health, Telehealth
Bryan McLaughlin
CEO
LUNOSA (Somerville, MA, USA) is a health technology company developing a minimally-invasive, self-expandable neuromodulation therapy for treating obstructive sleep apnea.
Therapeutic: Neuromodulation-Neurostimulation; Medical Devices
Kelly Mottet
COO
MACH32 (Edmonton, Alberta, Canada) is addressing the unmet medical need of prehospital traumatic bleeding. We are simplifying the delivery of a generic, clinically proven bleeding control drug called Tranexamic Acid (TXA), which decreases the risk of death due to bleeding by 1/3. TXA is a time-sensitive medication and is most effective when given immediately following injury; however, less than 5% of eligible patients receive TXA in time. This is because TXA is difficult to delivery and requires establishing an IV. We're solving the delivery problem by developing IMSAFE, a novel high-volume autoinjecotr for TXA. IMSAFE provides fast and easy deliver of TXA; it is an "EpiPen" for trauma.
Therapeutic: Emergency traumatic bleeding
Mike Kijewski
CEO
We know that each day of delay to market, or lost data causes risk to the business. Medcrypt (San Diego, CA) is here to help you quickly meet the regulatory and compliance requirements as set by the FDA, maintain cybersecurity posture over a device's lifetime, and support ongoing clinical care delivery.
Therapeutic: Our cybersecurity solutions are for any medical device running software
Alan Lucas
CEO
Navigation Sciences™ (Brookline, MA/ USA) is a clinical stage company developing the NaviSci™ Intelligent Surgical System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical hardware to guide precise surgical resection by enabling, for the first time, real-time in-vivo margin measurement. The system is designed to improve surgical outcomes, reduce recurrence risk, conserve lung function, shorten hospital length of stay, and enhance surgical workflow.
Therapeutic: Surgery, Surgical Oncology
Andrea Borsic
CEO & Founder
NE Scientific (Boston, MA, USA) applies Computer Science and AI to the simulation and guidance of surgical procedures improving clinical outcomes. In the context of oncological ablation, NE Scientific has demonstrated, in a world-first NIH sponsored clinical trial, a reduction of three times in the recurrence of liver cancer when the procedure is conducted under the guidance of the company's software. NE Scientific has recently entered into a licensing deal in the neurosurgery space, expanding the company’s line of products.
Therapeutic: Precision Medicine, Surgical Guidance in Oncology
Cristian Atria
Founder & CEO
nView medical (Salt Lake City, UT) develops breakthrough image guidance technology for surgery. We use AI image reconstruction to provide 3D images with an order of magnitude less radiation and less time. We provide AI-enabled guidance as well as surgical navigation. The nView s1 system is FDA cleared, clinically proven and in commercial stage.
Therapeutic: Imaging & Surgical Guidance
Sahan Ranamukhaarachchi
CEO
ProtonPetal CKM One from ProtoIntel (Vancouver, BC, Canada) is the only potassium monitor that can keep patients from crashing into dialysis – it will give clinicians the data/confidence to prescribe guideline directed therapies to their patients, which is the most evidence-based way to preserve kidney function; and it will give patients the ability to learn and optimize their lifestyle/diet and seek help if they’re in danger. They have the entire kidney care ecosystem activated and waiting to work with them.
Therapeutic: Biomarkers; Remote Patient Monitoring, Renal, Cardiovascular
John Blake
CFO
SLT IVUS by Provisio Medical, Inc. (San Diego, CA USA) provides physicians with automatic, real-time measurements of blood vessel lumen diameter and cross-sectional area to enable the selection of appropriate stent and balloon sizes for interventions. SLT IVUS eliminates physician image interpretation and inter-physician variances, with less time and cost than current devices and seamlessly integrates into current devices/workflows. Today, over 85% of vascular interventions occur without the benefit of intravascular measurement despite clinical data demonstrating reductions of amputations and other major adverse events by over 30%.
Therapeutic: Cardiovascular
Chris Bullock
CEO
QV Bioelectronics (Cheshire, UK) are a cutting-edge medical device startup based in the Northwest of England. They are developing the world’s first implantable electric field therapy device to treat aggressive brain cancers. Implantable bioelectronics is at the forefront of emerging healthcare technology, combining the use of cutting-edge materials and interdisciplinary science. QV are pioneering its use in cancer care. Their technology strives to provide longer, better quality lives for these patients.
Therapeutic: Oncology
Dimitrios Angelis
President & Co-Founder
Sparta Biomedical (Morrisville, NC, USA) has a revolutionary cartilage repair device that immediately restores mobility, while reducing pain in patients with knee osteoarthritis.
Therapeutic: Orthopedics-Spine; Orthopedics
Tarek Makansi
President and CTO
StimAire (Tucson, AZ, USA) has a patented injectable+wearable neuromodulator for treating Obstructive Sleep Apnea. This device presents similar electrophysiology as pacemaker-like implants, but replaces surgery in the operating room with an injection in the doctor’s office, enabling immediate recovery and much lower cost. StimAire completed a first-in-human study of safety and efficacy: no adverse events occurred and efficacy was as expected. The technology can be applied to overactive bladder, epilepsy, peripheral pain, etc. Injectable has only passive components and no ASIC is needed.
Therapeutic: Neuromodulation-Neurostimulation; Obstructive Sleep Apnea
Attila Borbáth
CEO & Co-founder
Synergia Medical (Belgium) is a preclinical stage company developing an innovative approach to improve the care of people suffering from treatment-resistant neurological disorders. The company’s novel technology is the first, non-metal neural stimulation platform that uses optoelectronics to deliver electrical pulses to the nerves or brain. By using optical fibers instead of standard metal wires, the Synergia platform enables the safe use of MRI exams, addressing a critical unmet need for understanding neurological disease progression and delivering better, more personalized treatment.
Therapeutic: Neuromodulation-Neurostimulation
Boris Pasche
President & CEO
TheraBionic (Winston-Salem, NC) has developed a medical device for the systemic targeted treatment of cancer. The technology is based on the discovery of tumor-specific amplitude-modulated radiofrequencies. The device delivers whole-body low-level radiofrequencies (RF) electromagnetic fields targeting tumor cells by means of a spoon-shaped antenna. Treatment is self-administered daily for three hours at home. The TheraBionic device has received Humanitarian Use Designation from the FDA and is expected to receive FDA approval for the treatment of hepatocellular carcinoma in 2023.
Therapeutic: Oncology, Hepatocellular carcinoma
Arun (Arundhuti) Ganguly
CTO & COO
TibaRay (Santa Clara, California, USA) is an early stage company developing a new Radiation Therapy system that will treat cancer patients in a fraction of a second, resulting in dramatically reduced collateral damage to normal tissue leading to better outcomes. The enabling technological breakthrough that came out of the SLAC National Accelerator Lab and Stanford University Healthcare uniquely positions TibaRay to disrupt this $7B market by curing cancer in a FLASH.
Therapeutic: Oncology
Robert Krummen
CEO
Vektor Medical (San Diego, CA, USA) is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias with its augmentative cardiac arrhythmia analysis technology, vMap. vMap is an FDA cleared, AI-based arrhythmia analysis tool that has been shown in clinical studies to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. It is the only non-invasive arrhythmia analysis solution on the market today that uses just the data from a 12-lead ECG to accurately analyze and visualize the source location of an arrhythmia across all four heart chambers.
Therapeutic: Cardiovascular
Raj Nihalani
CMO
Vibrant Gastro (Boston, MA, USA) is the pioneer of the Synchronized Activation Method™, a first-in-class drug-free technology that is the driving force behind the Vibrant system. This state-of-the-art system utilizes pre-programmed microvibrations to stimulate the colon mechanically, improving natural colonic motility1. Vibrant is for the treatment of adults with chronic idiopathic constipation (CIC) who have not experienced relief with the use of laxative therapies at the recommended dosage for at least one month. The Synchronized Activation Method™ opens the door to future indications for data-driven personalized treatments that leverage the gut-brain connection via the Enteric Nervous System (ENS) pathway.
Therapeutic: Gastroenterology; Medical Technology/Device
Toon Overbeeke
Co-founder & CEO
Vitestro’s (Utrecht, the Netherlands) autonomous venipuncture device meets a largely unmet need of solving significant healthcare staff shortages partly caused by a labor intensive and unautomated blood drawing procedure performed ~10 billion times p.a. globally. Their device is state of the art technology using AI and robotics, clinically validated with >2,000 patients. With their team of >50 people and backed by Sonder Capital, they are in the final stage of development and expect to be on the European market in 2024.
Therapeutic: Robotics, Diagnostics
